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Sir,
We thank Professor Jung for his interest in our work and
congratulate him on both his previous published work and his
more recent small demonstrative study.
As he correctly states, serum analysis was employed, without
clot activators, for our own pilot study, initiated before his and
other authors’ publications on choice of substrate. Technical
details in minutiae form were not included in the final submitted
paper for reasons of brevity and space constraints. However, it is
almost universally agreed that, without similar space constraints,
further details, particularly pertaining to pre-study planning,
serum acquisition and post-venesection processing would be
useful. Furthermore, description of quality control measures and
internal control methods would be useful adjuncts for those
wishing to replicate work done.
However, Professor Jung may have overlooked the underlying
premise and methodology of our study in that this represented a
comparative analysis of total detectable levels of serum MMP9,
collected under tightly controlled protocols, for the prediction of
the presence of significant colorectal pathology.
The absolute levels obtained were less critical in this study
than the relative levels seen within the population measured,
harbouring colorectal neoplasia or otherwise. No assertion is
made that the absolute serum MMP9 levels are applicable to the
general population as a whole, nor cohorts in different regions/
countries.
In addition, choice of assay employed in measurement has
significant effects on the absolute levels reported, whether total/
active/proenzyme or complexed protein is measured. Once again,
in a study design as employed in our pilot study, relative levels
within a population providing its own controls are more useful
than imported levels obtained under potentially varied conditions
elsewhere.
Professor Jung’s final comments regarding sample type of choice
are noted with appreciation, and further discussion will no doubt
ensue within the research group.
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